Tag: MindMed - Psilocybin Alpha

New Resource: Psychedelics Drug Development Tracker

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

MindMed Announces the Start of the First-Ever Clinical Trial Combining MDMA and LSD

Post published:January 20, 2021
Post category:Press Release

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Post published:January 14, 2021
Post category:Press Release

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

Post published:January 12, 2021
Post category:Press Release

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

MindMed Closes Upsized Financing of CAD $92.1m (USD $72.7m) to Meet High Investor Demand

Post published:January 7, 2021
Post category:Press Release

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Final Prospectus In Connection With Bought Deal Equity Financing

Post published:January 4, 2021
Post category:Press Release

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

MindMed Files Preliminary Prospectus In Connection With Bought Deal Equity Financing

Post published:December 21, 2020
Post category:Press Release

MindMed Upsizes Previously Announced Bought Deal Public Offering

MindMed Upsizes Previously Announced Bought Deal Public Offering

Post published:December 15, 2020
Post category:Press Release

MindMed Announces $50 Million Bought Deal Public Offering

MindMed Announces $50 Million Bought Deal Public Offering

Post published:December 15, 2020
Post category:Press Release

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

MindMed Announces Successful Completion of Pre-IND Meeting with the FDA for Project Lucy

Post published:December 14, 2020
Post category:Press Release

MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m)

MindMed Closes Upsized Financing of CAD $34.5m, Gross Proceeds Raised Since Company Founding Now Total CAD $121.4m (USD $94.8m)

Post published:December 11, 2020
Post category:Press Release

End of content

No more pages to load

Psilocybin Alpha

The definitive resource for investors in the emergent psychedelic medicine sector. Cut through the shroom stock noise with exclusive news, interviews, data and private financing opportunities.

Quick Links

Newsletter

Industry insights and interviews delivered to your inbox. No spam, just valuable information.